We are live on ! Find out more
SRPT icon

Sarepta Therapeutics
SRPT

179 hedge funds and large institutions have $1.21B invested in Sarepta Therapeutics in 2017 Q1 according to their latest regulatory filings, with 39 funds opening new positions, 64 increasing their positions, 44 reducing their positions, and 28 closing their positions.

New
Increased
Maintained
Reduced
Closed

97% more call options, than puts

Call options by funds: $108M | Put options by funds: $54.9M

45% more repeat investments, than reductions

Existing positions increased: 64 | Existing positions reduced: 44

39% more first-time investments, than exits

New positions opened: 39 | Existing positions closed: 28

11% more capital invested

Capital invested by funds: $1.08B → $1.21B (+$123M)

2.09% more ownership

Funds ownership: 72.29% → 74.38% (+2.1%)

1% more funds holding

Funds holding: 177 → 179 (+2)

50% less funds holding in top 10

Funds holding in top 10: 4 → 2 (-2)

Holders
179
Holders Change
+2
Holders Change %
+1.13%
% of All Funds
4.46%
Holding in Top 10
2
Holding in Top 10 Change
-2
Holding in Top 10 Change %
-50%
% of All Funds
0.05%
New
39
Increased
64
Reduced
44
Closed
28
Calls
$108M
Puts
$54.9M
Net Calls
+$53.5M
Net Calls Change
+$36.4M

Top Buyers

Rank Fund Capital Flow
1
BlackRock
BlackRock
New York
+$160M
2
HM
HealthCor Management
New York
+$48M
3
CCM
Camber Capital Management
Massachusetts
+$41.8M
4
O
OrbiMed
New York
+$32.6M
5
PC
PointState Capital
New York
+$19.8M

Top Sellers

Rank Fund Capital Flow
1
SM
Sabby Management
Florida
-$62.4M
2
PA
Perceptive Advisors
New York
-$30.9M
3
ACA
Avoro Capital Advisors
New York
-$27.7M
4
JG
Jefferies Group
New York
-$26M
5
Point72 Asset Management
Point72 Asset Management
Connecticut
-$17.5M
Name Holding Trade Value Shares
Change 		Change in
Stake
BlackRock
1
BlackRock
New York
$157M +$160M +5,175,193 +4,403%
Vanguard Group
2
Vanguard Group
Pennsylvania
$121M +$5.48M +176,966 +5%
State Street
3
State Street
Massachusetts
$94.6M +$17.3M +559,342 +21%
CC
4
Carlson Capital
Texas
$54.6M -$11.1M -357,063 -16%
PA
5
Perceptive Advisors
New York
$52.4M -$30.9M -998,800 -36%
HM
6
HealthCor Management
New York
$45.9M +$48M +1,550,000 New
TCP
7
Tourbillon Capital Partners
New York
$45.5M -$2.9M -93,838 -6%
CCM
8
Camber Capital Management
Massachusetts
$40M +$41.8M +1,350,000 New
Fidelity Investments
9
Fidelity Investments
Massachusetts
$33.2M -$2.31M -74,800 -6%
O
10
OrbiMed
New York
$31.2M +$32.6M +1,054,300 New
EA
11
Emerald Advisers
Pennsylvania
$24.2M +$8.36M +270,134 +49%
Point72 Asset Management
12
Point72 Asset Management
Connecticut
$23.8M -$17.5M -564,299 -41%
PC
13
PointState Capital
New York
$18.9M +$19.8M +638,900 New
Northern Trust
14
Northern Trust
Illinois
$18M +$876K +28,301 +5%
Citadel Advisors
15
Citadel Advisors
Florida
$18M +$4.82M +155,768 +34%
EMFAT
16
Emerald Mutual Fund Advisers Trust
Pennsylvania
$17.9M +$6.25M +201,942 +50%
EAM
17
Eagle Asset Management
Florida
$17.7M +$190K +6,137 +1%
Norges Bank
18
Norges Bank
Norway
$17M +$5.13M +165,601 +41%
Jennison Associates
19
Jennison Associates
New York
$16.7M – – –
ECP
20
Elk Creek Partners
Colorado
$16.7M +$7.62M +246,059 +78%
Goldman Sachs
21
Goldman Sachs
New York
$15.8M +$9.12M +294,529 +124%
TCM
22
Tekla Capital Management
Massachusetts
$15.1M +$1.4M +45,300 +10%
SFM
23
Sphera Funds Management
Israel
$14.3M +$2.63M +85,000 +21%
Balyasny Asset Management
24
Balyasny Asset Management
Illinois
$13M +$7.91M +255,602 +139%
Geode Capital Management
25
Geode Capital Management
Massachusetts
$12.5M +$916K +29,603 +8%
1
2 3 4 5

SRPT Hedge Fund Activity: Q1 2017 in Review

179 of the 4,017 institutional investors tracked by Wall St. Rank reported a position in Sarepta Therapeutics (SRPT) for Q1 2017, worth a combined $1.21B — up 11% from $1.08B a quarter earlier.

Buyers outnumbered sellers: 39 funds opened new SRPT positions and 28 closed out — a net gain of 11 holders — while 64 added to existing stakes and 44 trimmed.

The largest buyer was BlackRock, adding an estimated $160M. The largest seller was Sabby Management, exiting entirely with an estimated $62.4M sold.

  • 179 institutional investors held Sarepta Therapeutics (SRPT) as of Q1 2017, up from 177 in Q4 2016.
  • Funds reported $1.21B of Sarepta Therapeutics stock for Q1 2017, up 11% quarter-over-quarter.
  • 39 funds opened new Sarepta Therapeutics positions in Q1 2017 and 28 closed out, a net change of +11 holders.
  • The largest Sarepta Therapeutics buyer in Q1 2017 was BlackRock, an estimated $160M added.
  • The largest Sarepta Therapeutics seller in Q1 2017 was Sabby Management, an estimated $62.4M sold.

Based on aggregated 13F filings for Q1 2017.